Pfizer Q3 2026: Seven Straight EPS Beats Despite Paxlovid's 63% Drop

As seen on the 24/7 Wall St. homepage on November 3, 2026.

PFE Pfizer
Q3 2026
EPS
$0.87
est $0.73 +19.5%
Revenue
$16.58B
est $15.88B +4.5%

Pfizer is outrunning its COVID hangover: Paxlovid sales fell 63%, yet full-year revenue guidance rose to $62 billion to $64 billion. That is the seventh straight quarter of topping EPS expectations.

Continue ReadingShow less

Pfizer's adjusted earnings of $0.87 per share beat expectations, the seventh straight quarter of topping EPS estimates.

Revenue of $16.58 billion cleared the forecast even as Paxlovid fell 63%, so the COVID fade is no longer setting the direction of results.

Sponsored

Oncology and specialty care now carry the growth, with Eliquis at $2.52 billion the largest revenue contributor in the quarter.

Management raised full-year 2026 revenue guidance to $62 billion to $64 billion, absorbing the Innovent Biologics in-licensing charge. That is the number investors weigh against the continuing COVID revenue fade.

Sources

Mentioned: PFE

Related Market Updates

PFE Pfizer
New 52-week high $30.52 +0.3% vs prior high · 2026-10-22
$31$27$22

Pfizer cleared $30 for the first time in a year, closing at $30.52 and topping its October 22 peak by 0.33%. The $173.9 billion drugmaker was trading near $23 twelve months ago.

Read more
PFE Pfizer
New 52-week high $29.21 +0.7% vs prior high · 2026-09-02
$30$26$23

Pfizer hit a fresh 52-week high at $29.21, topping its September 2 peak. The drugmaker is now trading at levels no buyer from the past year is underwater on.

Read more
52-week highs
5 stocks hit new 52-week highs this week
  • DELLDell Technologies$524.14+6.0%
  • SNOWSnowflake$337.18+5.7%
  • BOXBox$35.19+3.5%
  • PFEPfizer$28.45+1.6%
  • CVXChevron$208.6+1.2%

Five stocks cleared 52-week highs this week: Dell topped its prior peak by 6% at $524.14, with Snowflake close behind at 5.7%. Box, Pfizer and Chevron rounded out the list with narrower breakouts.

Read more